Tofacitinib, a JAK1/JAK3 inhibitor, has been approved for RA and psoriatic arthritis, whereas baricitinib is a JAK1/JAK2 inhibitor approved for RA and the treatment of AD in Europe. The gene discussed is JAK1; the disease is rheumatoid arthritis.